Predictive Oncology Correlations
| POAI Stock | USD 1.34 0.17 11.26% |
The correlation of Predictive Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Predictive Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Predictive Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Average diversification
The correlation between Predictive Oncology and NYA is 0.19 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Predictive Oncology and NYA in the same portfolio, assuming nothing else is changed.
Predictive |
The ability to find closely correlated positions to Predictive Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Predictive Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Predictive Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Predictive Oncology to buy it.
Moving together with Predictive Stock
| 0.65 | AHG | Akso Health Group | PairCorr |
| 0.73 | CVS | CVS Health Corp | PairCorr |
| 0.76 | SSY | SunLink Health Systems | PairCorr |
| 0.76 | TFX | Teleflex Incorporated Earnings Call This Week | PairCorr |
| 0.73 | XTNT | Xtant Medical Holdings Earnings Call Tomorrow | PairCorr |
| 0.86 | IDXX | IDEXX Laboratories Earnings Call Today | PairCorr |
| 0.79 | LNSR | LENSAR Inc | PairCorr |
| 0.88 | MASS | 908 Devices Financial Report 14th of May 2024 | PairCorr |
| 0.87 | MBOT | Microbot Medical Financial Report 15th of May 2024 | PairCorr |
| 0.75 | MMSI | Merit Medical Systems | PairCorr |
| 0.91 | MYND | MYnd Analytics Symbol Change | PairCorr |
| 0.65 | AFIB | Acutus MedicalInc | PairCorr |
Moving against Predictive Stock
| 0.89 | GCTK | GlucoTrack | PairCorr |
| 0.8 | SNDA | Sonida Senior Living | PairCorr |
| 0.74 | TNDM | Tandem Diabetes Care | PairCorr |
| 0.65 | JYNT | Joint Corp Financial Report 2nd of May 2024 | PairCorr |
| 0.43 | TLIS | Talis Biomedical Corp | PairCorr |
Related Correlations Analysis
| -0.66 | 0.71 | -0.87 | 0.57 | NVOS | ||
| -0.66 | -0.31 | 0.63 | -0.56 | HCA | ||
| 0.71 | -0.31 | -0.74 | 0.53 | ACHC | ||
| -0.87 | 0.63 | -0.74 | -0.52 | PNTG | ||
| 0.57 | -0.56 | 0.53 | -0.52 | AIH | ||
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Predictive Stock performing well and Predictive Oncology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Predictive Oncology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| NVOS | 5.97 | 0.07 | 0.01 | 0.10 | 6.69 | 15.56 | 49.00 | |||
| HCA | 1.01 | 0.09 | 0.06 | 0.14 | 1.29 | 2.73 | 9.69 | |||
| ACHC | 1.18 | (0.24) | 0.00 | (0.22) | 0.00 | 2.11 | 6.80 | |||
| PNTG | 1.84 | 0.40 | 0.24 | 0.27 | 1.54 | 3.45 | 13.80 | |||
| AIH | 5.72 | (0.11) | 0.00 | 0.26 | 0.00 | 13.33 | 44.39 |
Be your own money manager
Our tools can tell you how much better you can do entering a position in Predictive Oncology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Equity Analysis Now
Equity AnalysisResearch over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
| All Next | Launch Module |
Predictive Oncology Corporate Management
Elected by the shareholders, the Predictive Oncology's board of directors comprises two types of representatives: Predictive Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Predictive. The board's role is to monitor Predictive Oncology's management team and ensure that shareholders' interests are well served. Predictive Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Predictive Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Joshua MBA | Interim Officer | Profile | |
| BS BSc | VP RD | Profile | |
| Pamela MBA | Chief Officer | Profile | |
| Raymond Vennare | CEO Chairman | Profile | |
| DSc OD | VP Operations | Profile | |
| Julia Kirshner | Chief Officer | Profile |
Already Invested in Predictive Oncology?
The danger of trading Predictive Oncology is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Predictive Oncology is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Predictive Oncology. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Predictive Oncology is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Predictive Oncology offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Predictive Oncology's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Predictive Oncology Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Predictive Oncology Stock: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Predictive Oncology. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more detail on how to invest in Predictive Stock please use our How to Invest in Predictive Oncology guide.Note that the Predictive Oncology information on this page should be used as a complementary analysis to other Predictive Oncology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Complementary Tools for Predictive Stock analysis
When running Predictive Oncology's price analysis, check to measure Predictive Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Predictive Oncology is operating at the current time. Most of Predictive Oncology's value examination focuses on studying past and present price action to predict the probability of Predictive Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Predictive Oncology's price. Additionally, you may evaluate how the addition of Predictive Oncology to your portfolios can decrease your overall portfolio volatility.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |
Is Predictive Oncology's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Predictive Oncology. If investors know Predictive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Predictive Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.48) | Revenue Per Share 0.443 | Quarterly Revenue Growth (0.08) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of Predictive Oncology is measured differently than its book value, which is the value of Predictive that is recorded on the company's balance sheet. Investors also form their own opinion of Predictive Oncology's value that differs from its market value or its book value, called intrinsic value, which is Predictive Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Predictive Oncology's market value can be influenced by many factors that don't directly affect Predictive Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Predictive Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Predictive Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Predictive Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.